复发性或原发性晚期转移性宫颈癌（R / M CC）的预后不佳，5年生存率仅为16.5％，需要新型和改进的治疗方法来治疗这些患者。 目前，R / M CC的一线标准治疗从药物免疫检查点抑制剂pembrolizumab添加到基于铂的化疗的紫杉醇和贝伐单抗中受益。 此外，近年来，第二线治疗的新选项已经出现。本文回顾了当前正在研究的药物，并讨论了它们的相对靶点，疗效以及在R / M CC治疗领域内的潜力。本文将重点介绍近期发表的数据以及有关R / M CC患者正在进行的多种行动方式的重要临床试验，包括免疫疗法，抗体药物共轭物和酪氨酸激酶抑制剂。我们在clinicaltrials.gov中搜索正在进行的试验和pubmed.ncbi.nih.gov中搜索最近发表的试验数据，以及美国临床肿瘤学会（ASCO），欧洲医学肿瘤学会（ESMO），欧洲妇科肿瘤学会（ESGO）和国际妇科癌症学会（IGCS）的最近几年的会议记录。 当前吸引注意力的治疗包括新型药物免疫检查点抑制剂，治疗性疫苗，抗体药物共轭物（例如tisotumab vedotin），针对HER2的酪氨酸激酶抑制剂以及多靶点协同组合。

Recurrent or primary advanced metastatic CC (R/M CC) has a poor prognosis with a 5-year-survival rate of 16.5%, demanding novel and improved therapies for the treatment of these patients. First-line standard of care of R/M CC now benefits from the addition of the immune checkpoint inhibitor, pembrolizumab, to platinum-based chemotherapy with paclitaxel and bevacizumab. Additionally, new options for second-line treatment have become available in recent years.Here, we review current investigational drugs and discuss their relative targets, efficacies, and potential within the R/M CC treatment landscape. This review will focus on recently published data and key ongoing clinical trials in patients with R/M CC, covering multiple modes of action, including immunotherapies, antibody-drug conjugates and tyrosine kinase inhibitors. We searched clinicaltrials.gov for ongoing trials and pubmed.ncbi.nih.gov for recently published trial data, as well as recent years' proceedings from the annual conferences of the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), European Society of Gynaecological Oncology (ESGO) and the International Gynecologic Cancer Society (IGCS).Therapeutics currently attracting attention include novel immune checkpoint inhibitors, therapeutic vaccination, antibody-drug conjugates, such as tisotumab vedotin, tyrosine kinase inhibitors targeting HER2 and multitarget synergistic combinations.